Abstract:

The prevalence of HIV-1 drug resistance mutations in naive patients has been previously shown to differ greatly with the geographic origin. The purpose of this study was to prospectively estimate the prevalence of HIV-1 drug resistance in Greece by analyzing a representative sample of newly HIV-1 diagnosed patients, as part of the SPREAD collaborative study. Protease (PR) and partial reverse transcriptase (RT) sequences were determined from 101 newly diagnosed HIV-1 patients, in Greece, during the period September 2002--August 2003, representing one-third of the total newly diagnosed HIV-1 patients in the same time period. The prevalence of HIV-1 drug resistance was estimated according to the IAS-USA mutation table taking into account all mutations in RT and only major mutations in PR region. The overall prevalence of resistance was 9% [95% confidence interval (CI): 4.2--16.2%]. The prevalence of mutations associated with resistance to NRTIs was 5% (95% CI: 1.6--11.2%), for NNRTIs was 4% (95% CI: 1.1--9.8%), while no major resistance mutations were found in PR. No multi-class resistance was detected in the study population. The prevalence of resistant mutations in the recent seroconverters was 22%. For two individuals, there was clear evidence for transmitted resistance based on epidemiological information for a known source of HIV-1 transmission. The prevalence of the HIV-1 non-B subtypes and recombinants was 52%.

Notes:

Paraskevis, DMagiorkinis, EKatsoulidou, AHatzitheodorou, EAntoniadou, APapadopoulos, APoulakou, GPaparizos, VBotsi, CStavrianeas, NLelekis, MChini, MGargalianos, PMagafas, NLazanas, MChryssos, GPetrikkos, GPanos, GKordossis, TTheodoridou, MSypsa, VHatzakis, AengResearch Support, Non-U.S. Gov'tNetherlands2005/07/19 09:00Virus Res. 2005 Sep;112(1-2):115-22. doi: 10.1016/j.virusres.2005.03.004. Epub 2005 Apr 8.